1. ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo.
ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Top panel: Proportion of patients with an ACR20, ACR50, or ACR70 response at 12 weeks of treatment. Bottom panels: Proportion of patients with an ACR20, ACR50, or ACR70 response at 2, 4, 8, and 12 weeks of treatment. Statistical comparisons were based on the Fisher’s exact test of each dose versus placebo. * p < ACR: American College of Rheumatology; C: combined 4 mg + 8 mg baricitinib group; P: placebo.
Yoshiya Tanaka et al. J Rheumatol 2016;43:
©2016 by The Journal of Rheumatology